XERIS BIOPHARMA HOLDINGS, INC. (XERS) Revenue 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$291.8MFY2025 · since FY2020: $20.2M → $291.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $291.8M | +43.7% |
| FY2024 | $203.1M | +23.9% |
| FY2023 | $163.9M | +48.7% |
| FY2022 | $110.2M | +122.3% |
| FY2021 | $49.6M | +146.0% |
| FY2020 | $20.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More XERS financial trends
XERS Net incomeXERS Net marginXERS Gross profitXERS Gross marginXERS Operating incomeXERS Operating marginXERS Operating cash flowXERS Free cash flowXERS Capital expendituresXERS Return on equityXERS Stock buybacksXERS Dividends paidXERS Total assetsXERS Total liabilitiesXERS Shareholders’ equityXERS overview →